CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 80 enrolled
Drug / intervention
Ismigen +1 moredrug
Likely dose
Ismigen 7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04802616
NCT04802616Phase 3Completed

The Effect of Immunostimulation With Polyvalent Mechanical Bacterial Lysate on Changes in the Concentration of iNKT Cells in Children With Allergic Rhinitis.

Medical University of Lublin·interventional·Posted Mar 17, 2021·Updated Apr 5, 2022

In Brief

A Phase 3 clinical trial evaluating Ismigen and Placebo for Allergic Rhinitis Due to Grass Pollen. Completed, enrolled 80 participants across 1 site.

Detailed Summary

The aim of the study is to assess the effect of polyvalent mechanical bacterial lysate (PMBL, Ismigen) on the clinical course of grass pollen-induced allergic rhinitis (using: total nasal symptom score, visual analogue scale, peak nasal inspiratory flow measurement) in children aged 5 to 17 and to assess changes in the concentration of iNKT cells under the influence of the therapy. Half of the 80 participants will receive PMBL while the other half will receive placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPoland
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMar 17, 2021
Enrollment StartMar 22, 2021
Primary CompletionSep 30, 2021
Study CompletionOct 29, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.3 years ago

Interventions

Ismigendrug

Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24).

Placebodrug

Matched tablets without any active substance.